Natalizumab biosimilar (GENERIUM Pharmaceuticals)

那他利珠单抗生物类似药 (GENERIUM Pharmaceuticals)

Report date: 2024/04/23 10:49:14

Base Information

Drug NameNatalizumab biosimilar (GENERIUM Pharmaceuticals)
Drug Alias NameGNR-093
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-7Integrin alpha-4/beta-1
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenerium Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGenerium Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A